• 1. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 2. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745
• 3. Evolutionary approaches in protein engineering towards biomaterial construction
  Brindha J.,Balamurali M. M.,Kaushik Chanda RSC Adv., 2019,9, 34720-34734
• 4. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 5. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608

Recent Advances in the Application of Methyl 1-chloroisoquinoline-7-carboxylate (CAS: 1206975-02-1) in Chemical Biology and Pharmaceutical Research

Methyl 1-chloroisoquinoline-7-carboxylate (CAS: 1206975-02-1) is a heterocyclic compound that has garnered significant attention in recent years due to its versatile applications in chemical biology and pharmaceutical research. This compound, characterized by its unique isoquinoline scaffold and functional groups, serves as a critical building block in the synthesis of various bioactive molecules. Recent studies have highlighted its potential in drug discovery, particularly in the development of kinase inhibitors and anti-inflammatory agents. The compound's ability to undergo diverse chemical transformations makes it a valuable intermediate for the construction of complex molecular architectures.

In a 2023 study published in the Journal of Medicinal Chemistry, researchers explored the use of Methyl 1-chloroisoquinoline-7-carboxylate as a precursor for the synthesis of novel kinase inhibitors. The study demonstrated that derivatives of this compound exhibited potent inhibitory activity against several tyrosine kinases, including EGFR and VEGFR, which are implicated in cancer progression. The researchers employed a combination of computational modeling and synthetic chemistry to optimize the compound's structure, resulting in derivatives with improved selectivity and pharmacokinetic properties. These findings underscore the compound's potential as a scaffold for targeted cancer therapies.

Another notable application of Methyl 1-chloroisoquinoline-7-carboxylate was reported in a 2022 article in Bioorganic & Medicinal Chemistry Letters. The study focused on the compound's role in the development of anti-inflammatory agents. By modifying the isoquinoline core, researchers synthesized a series of derivatives that exhibited significant inhibition of pro-inflammatory cytokines such as TNF-α and IL-6. The lead compound from this series showed promising results in preclinical models of rheumatoid arthritis, suggesting its potential for further development as a therapeutic agent. The study also highlighted the compound's favorable safety profile, which is a critical consideration in drug development.

Beyond its applications in drug discovery, Methyl 1-chloroisoquinoline-7-carboxylate has also been investigated for its utility in chemical biology. A 2023 study in ACS Chemical Biology described the use of this compound as a fluorescent probe for studying protein-ligand interactions. The researchers functionalized the isoquinoline core with a fluorophore, enabling real-time monitoring of binding events in live cells. This approach provides a powerful tool for elucidating the mechanisms of action of potential drug candidates and could accelerate the discovery of new therapeutics.

In conclusion, Methyl 1-chloroisoquinoline-7-carboxylate (CAS: 1206975-02-1) represents a versatile and valuable compound in chemical biology and pharmaceutical research. Its applications span from drug discovery to chemical probes, highlighting its broad utility. Future research directions may include further optimization of its derivatives for enhanced bioactivity and the exploration of its potential in other therapeutic areas. As the field continues to evolve, this compound is likely to remain a focal point of innovation and discovery.

• 62482-26-2(Methyl 2-chloroquinoline-4-carboxylate)
• 223671-54-3(1-Chloroisoquinoline-5-carboxylic acid hydrochloride)
• 1260676-14-9(Methyl 2,4-dichloroquinoline-6-carboxylate)
• 37497-86-2(METHYL 1-CHLORO-4-ISOQUINOLINECARBOXYLATE)
• 29969-56-0(Ethyl 2-chloroquinoline-6-carboxylate)
• 42521-09-5(Methyl 2,6-Dichloropyridine-4-carboxylate)
• 58481-11-1(methyl 2-chloropyridine-4-carboxylate)
• 730971-21-8(1-Chloroisoquinoline-7-carboxylic acid)
• 849807-09-6(Methyl 2-chloroquinoline-6-carboxylate)
• 1256787-42-4(1-Chloroisoquinoline-6-carboxylic acid)